-
Brefeldin A: ER Stress Workflow Guide
2026-09-09
Use Brefeldin A to connect ER–Golgi trafficking defects with ER stress, protein quality control, and cancer-cell phenotypes in a single experimental framework. This guide pairs BFA dose–time optimization with transport imaging, apoptosis assays, migration studies, and UBR1/UBR2-centered mechanistic controls.
-
Norovirus Co-opts NINJ1 for Selective NS1 Secretion
2026-09-09
Song and colleagues show that murine norovirus repurposes the plasma-membrane rupture factor NINJ1 to secrete the viral protein NS1 after caspase-3 cleavage of NS1/2. The study combines CRISPR screening, genetic and pharmacological perturbation, protein-localization analysis, mutagenesis, and mouse infection models to connect selective viral protein release with intestinal infection.
-
Shrimp STING Reveals an Ancestral DNA-Sensing Axis
2026-09-08
Li and colleagues show that shrimp STING can directly bind double-stranded DNA as well as cyclic dinucleotides and activate an IFN-like antiviral program. The work defines a dsDNA–STING–IKKε–IRF–Vago4 axis in an arthropod, extending current models of how cytosolic nucleic-acid sensing evolved.
-
Caspase 3/7, Autophagy, and DNA Damage in Breast Cancer
2026-09-08
The 2025 reference study identifies CASP3 and CASP7 as active regulators of cytoprotective autophagy and the DNA damage response during non-lethal stress in human breast cancer cells. Its findings connect non-canonical CASP7 processing, PARP1 modulation, H2AX phosphorylation, and synthetic lethality with BRCA1 loss, offering a mechanistic framework for interpreting stress-adaptation experiments.
-
circ_0042103/TAF15/NER Axis in Pulpitis
2026-09-07
The reference study identifies circ_0042103 as a regulatory link between inflammatory signaling, DNA damage, and nucleotide excision repair in dental pulp stem cells. Its integrated tissue, sequencing, molecular-interaction, and functional experiments support a circ_0042103/TAF15/NER axis that may help explain how inflammation becomes sustained in pulpitis.
-
Deferoxamine Mesylate at the Lysosome–Iron Interface
2026-09-05
Deferoxamine mesylate is more than an iron-chelating agent: it can help researchers interrogate how iron availability intersects with lysosomal stress, ferritinophagy, and HIF-1α signaling. This article translates recent TCF25 findings into a practical framework for designing nutrient-starvation, oxidative stress, and tissue-protection assays.
-
Dimetridazole Workflows for Antimicrobial Research
2026-09-05
Dimetridazole supports more than a conventional growth-inhibition screen: it can be evaluated as a combination potentiator, quorum sensing inhibitor, membrane-disruption probe, and electrochemical sensing target. This practical workflow connects bacterial culture assay design with mechanistic validation and carefully staged infection model research.
-
Lyso-Tracker Red for Nanovaccine Lysosome Assays
2026-09-04
Learn how Lyso-Tracker Red supports live-cell analysis of nanoparticle trafficking, lysosomal acidification, and escape in antigen-presenting cells. This practical guide combines product-specific handling with assay controls inspired by a polyethyleneimine-modified laminarin nanovaccine study.
-
7-dehydro Cholesterol: DHCR7 Assay Workflows
2026-09-04
Use 7-dehydro Cholesterol to connect DHCR7-dependent sterol flux with UVB-driven vitamin D3 formation, oxidation, and immune phenotypes. This workflow-focused guide contrasts substrate supplementation with genetic disruption and translates recent fish data into practical assay controls.
-
Thermal-Protective Hydrogel for Curative Tumor Ablation
2026-09-03
The reference study develops an injectable MR@CaP@HA hydrogel that combines local thermal insulation with pH- and glutathione-responsive delivery of mitoxantrone and Resiquimod (R-848) during radiofrequency ablation. By protecting adjacent tissue while promoting immunogenic cell death, dendritic-cell maturation, and M1 macrophage polarization, the platform improved residual-tumor control and achieved complete tumor eradication in a subset of animals.
-
CDK4/6–BET Synergy in Pancreatic Cancer
2026-09-03
Gu et al. show that combining the CDK4/6 inhibitor palbociclib with the BET inhibitor JQ1 suppresses pancreatic ductal adenocarcinoma more effectively than either agent alone. The study identifies GSK3β-mediated Wnt/β-catenin activation and its crosstalk with TGF-β/Smad signaling as a mechanistic explanation for why combination treatment can counteract the pro-invasive effects of CDK4/6 inhibition.
-
E-64d for Reproducible Cell Viability Assays
2026-09-02
Learn how E-64d (SKU A1903) can clarify calpain- and cathepsin-dependent effects in cell viability, proliferation, and apoptosis assays. This scenario-based guide covers mechanism, controls, stock preparation, interpretation, and practical vendor-selection criteria.
-
Dual-Action Inhibitors Accelerate p38α Dephosphorylation
2026-09-02
The reference study shows that selected p38α MAP kinase inhibitors can both suppress catalytic activity and increase WIP1-mediated removal of the activation-loop phosphothreonine. Structural comparisons explain this effect and suggest that controlling kinase conformation may improve the durability and selectivity of kinase-directed inhibition.
-
Epacadostat (INCB024360) Workflow Guide
2026-09-01
Build a reproducible IDO1 inhibition workflow by combining Epacadostat dose–response testing with standardized whole-blood stimulation, kynurenine tracking, and immune-function readouts. The approach helps distinguish direct metabolic blockade from donor, cytokine, or checkpoint-combination effects in immuno-oncology research.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-09-01
Oliveira and colleagues show that naturally occurring angiotensin fragments can alter SARS-CoV-2 spike-protein binding to AXL, ACE2, and NRP1 in receptor-binding assays. The work identifies peptide length, N-terminal sequence, and tyrosine modification as important determinants, while indicating that the findings remain an in vitro biochemical observation rather than evidence of altered infection or clinical risk.